A Study of LY3022855 In Participants With Breast or Prostate Cancer
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about how the investigational drug,
LY3022855, affects the immune system in participants with advanced breast or prostate cancer
that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6
weeks).